CHEPLAPHARM Arzneimittel GmbH

Publications

This section provides relevant information as well as ongoing and timely updates on the strategic and operative success stories of our steadily growing Company.

support_agent

Your contact persons

Jens Remmers

Head of Treasury & Investor Relations

IR center of information

Financial Reports

02nd June 2022
Investor Call Quarterly Report Q1 2022
31st May 2022
Publication Quarterly Report Q1 2022
10th May 2022
Investor Call Full Financial Year 2021 audited
29th April 2022
Publication Full Financial Year 2021 audited
30th November 2021
Investor Call Quarterly Report Q3 2021
19th November 2021
Publication Quarterly Report Q3 2021
24th August 2021
Investor Call Quarterly Report Q2 2021
20th August 2021
Publication Quarterly Report Q2 2021
Find out how you can benefit

Publications

The latest from CHEPLAPHARM

Investors Domain

01/04/2021

CHEPLAPHARM acquires rights to Atacand® in more than 70 markets

more chevron_right
Press releases

01/04/2021

CHEPLAPHARM acquires rights to Atacand® in more than 70 markets

more chevron_right
Press releases

12/21/2020

CHEPLAPHARM donates over €200,000 for Christmas

more chevron_right
Investors Domain

12/16/2020

CHEPLAPHARM proves its vigour

more chevron_right
Press releases

12/16/2020

CHEPLAPHARM proves its vigour

more chevron_right
Investors Domain Investor Relations Archive

11/02/2020

CHEPLAPHARM closes another product portfolio acquisition

more chevron_right
Archive Investor Relations Investors Domain

11/02/2020

CHEPLAPHARM closes another product portfolio acquisition

more chevron_right
Investor Relations Archive

10/15/2020

CHEPLAPHARM succeeds again: 1 Billion Euros (equivalent) of Senior Secured Notes placed with institutional Investors

CHEPLAPHARM Arzneimittel GmbH has successfully gained a foothold in the US American institutional bond market.


more chevron_right
Investors Domain

10/15/2020

CHEPLAPHARM succeeds again: 1 Billion Euros (equivalent) of Senior Secured Notes placed with institutional Investors

CHEPLAPHARM Arzneimittel GmbH has successfully gained a foothold in the US American institutional bond market.


more chevron_right
Investor Relations Archive

10/08/2020

CHEPLAPHARM announces pricing of Senior Secured Notes

CHEPLAPHARM Arzneimittel GmbH Announces Pricing of €575 Million 4.375% Senior Secured Notes due 2028 $500 Million 5.500% Senior Secured Notes due 2028


more chevron_right

Investor Relations topics

Back to top expand_less